Entire Portfolio
print

Composition of the portfolio as of December 31, 2014

Celgene   11.7%
Isis Pharmaceuticals   10.4%
Incyte   8.4%
Gilead   7.8%
Actelion   7.5%
Agios Pharmaceuticals   5.9%
Vertex Pharmaceuticals   4.5%
Medivation   3.9%
Alexion Pharmaceuticals   3.5%
Radius Health   3.0%
Synageva BioPharma   3.0%
Puma Biotechnology   2.8%
Pharmacyclics   2.5%
Novo Nordisk   2.4%
Regeneron Pharmaceuticals   2.3%
Receptos   2.3%
Alnylam Pharmaceuticals   2.1%
Swedish Orphan Biovitrum   2.0%
Neurocrine Biosciences   1.9%
Halozyme Therapeutics   1.9%
PTC Therapeutics   1.8%
Tetraphase Pharmaceuticals   1.5%
Novavax   1.3%
Infinity Pharmaceuticals   1.1%
Clovis Oncology   1.0%
Tesaro   0.7%
Probiodrug   0.7%
Immunogen   0.6%
Cempra   0.5%
Theravance   0.4%
Achillion Pharmaceuticals   0.4%
Theravance Biopharma   0.2%
     
     
Radius Health Warrants 23.04.2018   <0.1%
Radius Health Warrants 19.02.2019   <0.1%
Cubist Pharmaceuticals Contingent Value Rights - ex Optimer   <0.1%
Cubist Pharmaceuticals Contingent Value Rights - ex Trius   0.0%
     
Total Securities   CHF 3 523.8 mn
     
Other assets   CHF 9.0 mn
Other payables   CHF (40.3) mn
     
total shareholder's equity   CHF 3 492.5 mn
Treasury shares (in % of company) 1)   4.8%

 

1) Correspond to the total of all own shares held including the second trading line